Is Vertex Pharmaceuticals Stock Still a Strong Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX), a top-shelf rare-disease drugmaker, posted stellar fourth-quarter results after the closing bell Thursday. The company absolutely crushed Wall Street's consensus bottom- and top-line estimates for the three-month period, thanks to the outstanding performance of its new cystic fibrosis (CF) medication Trikafta, along with other key CF drugs like Symdeko/Symkevi.

Is Vertex's stock a strong buy on the heels of this outstanding Q4 report? That's a tricky question to answer. At present, Vertex sports one of the richest valuations in the entire healthcare sector, which would seem to indicate that this quarterly beat was already baked into the biotech's share price. A deeper look under the hood, however, reveals that this highly prized rare disease company is still a great buy for long-term investors. Here's why.

Image Source: Getty Images.

Source Fool.com